Gastroenterology
AMG 706 shows activity in phase II trial of patients with imatinib-resistant stomach tumors
Published in Telemedicine Week, December 5th, 2006
In this study, AMG 706 showed encouraging clinical activity in patients with advanced high-dose imatinib-resistant gastrointestinal stromal tumors (GIST). These data were presented in an oral session at the Connective Tissue Oncology Society (CTOS) meeting in Venice, Italy.
"AMG 706 targets tyrosine kinases, a family of proteins thought to play an important role in controlling cell development and tumor growth," said Robert Benjamin, MD, chair, Sarcoma Medical Oncology professor, M.D. Anderson Cancer...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Telemedicine Week
Source: Telemedicine Week (2006-12-05)
More Articles from Telemedicine Week
- Allergies
New allergies study findings have been reported by scientists at College of Medicine, Division of Pediatric Gastroenterology - Allergies
Studies from Institute of Medical Research have provided new information about allergies - Aneurysm
New aneurysm research from University of California outlined - Angiogenesis
Reports outline angiogenesis study results from Royal Free Hospital, Department of Surgery - Angiogenesis
Studies from Nanjing Medical University, Department of Cardiovascular Medicine in the area of angiogenesis published - Angiography
Investigators at Downstate Medical Center, Department of Medicine target angiography - More from this issue of Telemedicine Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
